Stocks · News reference
Revvity shares are trading lower after the company despite reporting better-than-expected Q2 financial results and raising its FY26 adjusted EPS above estimates. The company raised its FY26 sales guidance with its midpoint below estimates.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Global Multiplex Assays Market 2026 Edition - Consumables Dominate Multiplex Assays with 68% Market Share
The global multiplex assays market is projected to grow from US$6.8 billion in 2025 to US$12.4 billion by 2030, at a 12.8% CAGR. North America leads with 34% market share, while Asia Pacific is the fastest-growing region at 15.5% CAGR. Consumables dominate with 68% market share, and protein multiplex assays hold 42%. Growth is driven by precision medicine, companion diagnostics, and laboratory automation.
RBC Capital Initiates Coverage On Revvity with Sector Perform Rating, Announces Price Target of $135
RBC Capital analyst Dan Leonard initiates coverage on Revvity (NYSE:RVTY) with a Sector Perform rating and announces Price Target of $135.
Evercore ISI Group Maintains Outperform on Revvity, Raises Price Target to $126
Evercore ISI Group analyst Vijay Kumar maintains Revvity (NYSE:RVTY) with a Outperform and raises the price target from $125 to $126.